- Home
- DTIL vs RNA Comparison
DTIL vs RNA Comparison
Compare DTIL & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTIL | RNA |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.9M | 222.5M |
| IPO Year | 2019 | 2025 |
Fundamental Metrics
Financial Performance| Metric | DTIL | RNA |
|---|---|---|
| Price | $6.36 | $8.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 20 |
| Target Price | $45.00 | ★ $69.26 |
| AVG Volume (30 Days) | 231.4K | ★ 347.8K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,070,000,000.00 | N/A |
| Revenue This Year | N/A | $88.12 |
| Revenue Next Year | N/A | $18.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.53 | $8.66 |
| 52 Week High | $9.62 | $73.06 |
Technical Indicators
Market Signals| Indicator | DTIL | RNA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 30.69 |
| Support Level | N/A | N/A |
| Resistance Level | N/A | $14.39 |
| Average True Range (ATR) | 0.00 | 0.73 |
| MACD | 0.00 | -0.27 |
| Stochastic Oscillator | 0.00 | 10.85 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.